GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TFF Pharmaceuticals Inc (NAS:TFFP) » Definitions » 5-Year Yield-on-Cost %

TFF Pharmaceuticals (TFF Pharmaceuticals) 5-Year Yield-on-Cost % : 0.00 (As of May. 02, 2024)


View and export this data going back to 2019. Start your Free Trial

What is TFF Pharmaceuticals 5-Year Yield-on-Cost %?

TFF Pharmaceuticals's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for TFF Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:



TFFP's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.855
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of TFF Pharmaceuticals's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, TFF Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TFF Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TFF Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where TFF Pharmaceuticals's 5-Year Yield-on-Cost % falls into.



TFF Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of TFF Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

TFF Pharmaceuticals  (NAS:TFFP) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


TFF Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of TFF Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


TFF Pharmaceuticals (TFF Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.
Executives
Carlson Capital L P 10 percent owner 2100 MCKINNEY AVE, STE 1900, DALLAS TX 75201
Clint Duane Carlson 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Zamaneh Mikhak officer: Chief Medical Officer 1751 RIVER RUN, SUITE 400, C/O TFF PHARMACEUTICALS, INC., FORT WORTH TX 76107
Robert S Mills director 8 MISTY BROOK LANE, NEW FAIRFIELD CT 06812
Kirk Allen Coleman officer: CFO, Secretary, and Treasurer 2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
Stephen Rocamboli director C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Asgard Investment Corp. Ii 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Double Black Diamond Offshore Ltd 10 percent owner CITCO FUND SERVICES, 89 NEXUS WAY, P.O. BOX 31106, CAMANA BAY E9 KY-1205
Harlan F Weisman director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Brandi Roberts director 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Randy H Thurman director 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Glenn R. Mattes director, officer: President and CEO 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Malcolm Fairbairn director C/O ASCEND CAPITAL, LLC, 4 ORINDA WAY, SUITE 200-C, ORINDA CA 94563
Lung Therapeutics, Inc. 10 percent owner P.O. BOX 150183, AUSTIN TX 78715